Anbio Biotechnology (NNNN)
NNNN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/0001185185-26-001294-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NNNN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | Germany |
| IPO year | 2025 |
| SEC CIK | 0001982708 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8.6M |
| Net income | $6.4M |
| Operating income | $5.8M |
| Net margin | 74.1% |
| Operating margin | 66.7% |
| Revenue growth | +5.6% |
| Cash | $7.8M |
| Total assets | $30.2M |
| P/E (computed) | 87.2× |
| P/S (computed) | 64.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-07 |
| Cash and burn | $7.8M cash; operating cash flow -$1.7M a quarter. | Report 2025-12-31 |
| Shares outstanding | 143,891,200 (2025-12-31); 142,291,200 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | GGF CPA LTD, Guangzhou, China | PCAOB Form AP 2026-05-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $8.6M | $6.4M | -$6.7M | $7.8M | No debt tags | $8.6M | 20-F 2026-04-07 |
| FY 2024 2024-12-31 | $8.2M | $2.4M | $2.1M | $11.8M | No debt tags | $8.2M | 20-F 2026-04-07 |
| FY 2023 2023-12-31 | $6.7M | $2.3M | $898K | $9.7M | No debt tags | $6.7M | 20-F 2026-04-07 |
| FY 2022 2022-12-31 | $23.5M | $10.0M | $4.4M | $7.1M | No debt tags | $23.5M | 20-F 2025-04-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-02-19 |
| Latest annual report FORM 20-F | 20-F | 2026-04-07 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-05-19 |
Source: SEC EDGAR submissions feed, 43 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.8% |
| 1 month | -10.3% |
| 3 months | -62.8% |
| Year to date | -87.3% |
| 1 year | -83.6% |
| From 52-week high | -90.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier